emm5 Antibody
Description
Overview of Anti-MDA5 Antibodies
Anti-MDA5 antibodies target MDA5, a cytoplasmic RNA helicase involved in antiviral immune responses. These autoantibodies are strongly associated with clinically amyopathic dermatomyositis (CADM) and rapidly progressive interstitial lung disease (ILD) .
Clinical Correlations
A 2024 study (n=24 MDA5+ patients) revealed correlations between antibody subfragment recognition and disease manifestations :
| Clinical Feature | Associated MDA5 Subfragment | Antibody Titre Trend |
|---|---|---|
| Muscle involvement | Fragment F (aa 646-801) | Higher titres |
| Vascular dysfunction | Fragments B (aa 130-284) & E (aa 517-671) | Elevated vs. non-vascular cases |
| Fatal ILD progression | Fragment A (aa 1-155) | Higher titres |
| Sex-based differences | Fragment H (aa 905-1026) | Higher in females |
These findings suggest epitope-specific immune responses influence disease severity and organ involvement.
Diagnostic and Prognostic Utility
-
ILD Risk: Elevated anti-MDA5 antibody levels correlate with increased mortality due to ILD, particularly in Asian populations .
-
Therapeutic Implications: Early detection guides aggressive immunosuppressive therapy (e.g., corticosteroids, rituximab) to mitigate lung complications .
Research and Development
-
Assay Standardization: ELISA-based methods are critical for quantifying anti-MDA5 subfragment antibodies, enabling personalized treatment approaches .
-
Biomarker Potential: Fragment-specific antibody profiles may predict disease progression, though larger cohorts are needed for validation .
Comparative Table: Anti-MDA5 vs. Other Autoantibodies
| Parameter | Anti-MDA5 Antibodies | Anti-Jo1 Antibodies | Anti-Mi2 Antibodies |
|---|---|---|---|
| Target Antigen | MDA5 (IFIH1 gene product) | Histidyl-tRNA synthetase | Nuclear helicase |
| Primary Association | CADM with ILD | Polymyositis | Classic dermatomyositis |
| Mortality Driver | Rapidly progressive ILD | Chronic ILD | Low mortality |
| Treatment Response | Poor (high relapse risk) | Moderate | Good |
Future Directions
-
Epitope Mapping: Advanced structural analyses (e.g., cryo-EM) could elucidate how fragment-specific binding drives pathology .
-
Therapeutic Innovations: Engineered monoclonal antibodies or affinity reagents (e.g., Affimers, nanoMIPs) may neutralize pathogenic anti-MDA5 subsets while minimizing immunogenicity .
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
